Fundamentals of SGLT2is and GLP-1RAs for CV Risk

Listen to expert faculty discuss the fundamental science and the mechanism to evidence around new antihyperglycemic drugs, and why exactly this is such an important topic. This conversation focuses on the key principles of adding GLP-1RAs and SGLT2 inhibitors, and how using these drugs has been shown to have an important effect on reducing cardiovascular risk.

Supplemental Slides 

Educational grant support provided by: Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC

To visit the hub for the CV Risk in Diabetes: Emerging Science Grant, click here!

Clinical Topics: Dyslipidemia, Diabetes and Cardiometabolic Disease, Prevention

Keywords: Primary Prevention, Diabetes Mellitus, Dyslipidemias, Sodium-Glucose Transporter 2

< Back to Listings